| Literature DB >> 33584277 |
Qinghui Zheng1, Mengdi Zhang2, Fangfang Zhou3, Long Zhang2, Xuli Meng1.
Abstract
Drug resistance is a major challenge in breast cancer (BC) treatment at present. Accumulating studies indicate that breast cancer stem cells (BCSCs) are responsible for the BC drugs resistance, causing relapse and metastasis in BC patients. Thus, BCSCs elimination could reverse drug resistance and improve drug efficacy to benefit BC patients. Consequently, mastering the knowledge on the proliferation, resistance mechanisms, and separation of BCSCs in BC therapy is extremely helpful for BCSCs-targeted therapeutic strategies. Herein, we summarize the principal BCSCs surface markers and signaling pathways, and list the BCSCs-related drug resistance mechanisms in chemotherapy (CT), endocrine therapy (ET), and targeted therapy (TT), and display therapeutic strategies for targeting BCSCs to reverse drug resistance in BC. Even more importantly, more attention should be paid to studies on BCSC-targeted strategies to overcome the drug resistant dilemma of clinical therapies in the future.Entities:
Keywords: breast cancer stem cell signaling pathways; breast cancer stem cells; clinical therapy; drug resistance; surface markers
Year: 2021 PMID: 33584277 PMCID: PMC7876385 DOI: 10.3389/fphar.2020.599965
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810